A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Ki vehet részt

• A clinical diagnosis of nonsegmental vitiligo with depigmented area including all of the following:; ≥ 0.5 F-VASI on the face; ≥ 3.0 T-VASI (body areas not including the face); Total body vitiligo area (facial and nonfacial) not exceeding 10% BSA
• Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted

Ki nem vehet részt

• Previous adverse reaction to NB-UVB phototherapy that caused discontinuation of therapy
• Lack of response (little or no repigmentation) to prior NB-UVB phototherapy
• Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chicken pox) within 1 week before baseline
• Recent use of topical or systemic medications (including biologics or JAK inhibitors), or laser or phototherapy to treat vitiligo. Note: Recent may be defined differently for different treatments
• Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders
• History of thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction)
• Any other skin disease that, in the opinion of the investigator, would interfere with the study cream application or study assessments
• Any serious illness or medical, physical, or psychiatric condition(s) that pose a significant risk to the participant; or interfere with interpretation of study data
• Specific protocol-defined chemistry, hematology, and serological lab values
• No pigmented hair within any of the vitiligo areas on the face
• Used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas
• Those who are pregnant, lactating or considering pregnancy during the period of study participation